[{"id":"1b39475a-c778-482c-b273-baa5f64197c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114319","created_at":"2021-01-18T15:21:08.086Z","updated_at":"2024-07-02T16:34:59.273Z","phase":"Phase 1","brief_title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03114319","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e batoprotafib (TNO155) • nazartinib (EGF816)"],"overall_status":"Recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 06/11/2025","study_completion_date":" 06/11/2025","last_update_posted":"2024-06-04"},{"id":"4c522063-8eba-4680-acba-ac43c6debdef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02900664","created_at":"2021-01-18T14:14:11.436Z","updated_at":"2024-07-02T16:36:14.500Z","phase":"Phase 1","brief_title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","source_id_and_acronym":"NCT02900664","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • spartalizumab (PDR001) • nazartinib (EGF816) • CJM112 • Ilaris (canakinumab)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 03/17/2021","primary_completion_date":" 03/17/2021","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-03-29"},{"id":"2afc22d0-ba58-4ea0-ba5f-1c4ea04ee260","acronym":"","url":"https://clinicaltrials.gov/study/NCT03529084","created_at":"2021-01-18T17:22:29.583Z","updated_at":"2024-07-02T16:36:53.284Z","phase":"Phase 3","brief_title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","source_id_and_acronym":"NCT03529084","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • nazartinib (EGF816)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 08/13/2020","primary_completion_date":" 08/13/2020","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2019-11-22"}]